Literature DB >> 15699470

Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src.

Glaucia E Callera1, Rhian M Touyz, Rita C Tostes, Alvaro Yogi, Ying He, Sam Malkinson, Ernesto L Schiffrin.   

Abstract

Increasing evidence indicates that aldosterone elicits vascular effects through nongenomic signaling pathways. We tested the hypothesis that aldosterone induces activation of vascular mitogen-activated protein (MAP) kinases and NADPH oxidase via c-Src-dependent mechanisms in vascular smooth muscle cells (VSMCs). Aldosterone effects on activation of c-Src, p38MAP kinase, and NADPH oxidase, and incorporation of [3H]proline, an index of collagen synthesis, were assessed in cultured rat VSMCs. Studies were performed in the absence and presence of eplerenone, a selective mineralocorticoid receptor blocker, PP2, a selective Src inhibitor, and SB212190, a selective p38MAPK inhibitor. Phosphorylation of c-Src was dose-dependently increased by aldosterone, with maximal responses obtained at 10(-7) mol/L. Aldosterone increased p38MAP kinase phosphorylation, NAD(P)H oxidase activation, and [3H]proline incorporation. These responses were abrogated by eplerenone and almost abolished by PP2. Aldosterone-stimulated incorporation of [3H]proline was significantly reduced by SB212190, indicating that p38MAP kinase plays a role in profibrotic actions of aldosterone. To unambiguously demonstrate the importance of aldosterone in c-Src signaling, VSMCs from c-Src+/+ and c-Src+/- mice were also studied. Aldosterone increased phosphorylation of c-Src, p38MAP kinase, and cortactin, a Src-specific substrate, in c-Src+/+ VSMCs, but not in c-Src-deficient cells. Taken together, our findings demonstrate that nongenomic signaling by aldosterone occurs through c-Src-dependent pathways. These processes may play an important role in profibrotic actions of aldosterone.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15699470     DOI: 10.1161/01.HYP.0000154365.30593.d3

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  68 in total

1.  Aldosterone's rapid, nongenomic effects are mediated by striatin: a modulator of aldosterone's effect on estrogen action.

Authors:  Patricia Coutinho; Christopher Vega; Luminita H Pojoga; Alicia Rivera; Gregory N Prado; Tham M Yao; Gail Adler; Manuel Torres-Grajales; Enrique R Maldonado; Arelys Ramos-Rivera; Jonathan S Williams; Gordon Williams; Jose R Romero
Journal:  Endocrinology       Date:  2014-03-21       Impact factor: 4.736

2.  Hsp70 regulation on Nox4/p22phox and cytoskeletal integrity as an effect of losartan in vascular smooth muscle cells.

Authors:  Andrea Fernanda Gil Lorenzo; Victoria Bocanegra; María Eugenia Benardon; Valeria Cacciamani; Patricia G Vallés
Journal:  Cell Stress Chaperones       Date:  2013-06-13       Impact factor: 3.667

3.  Hck is a key regulator of gene expression in alternatively activated human monocytes.

Authors:  Ashish Bhattacharjee; Srabani Pal; Gerald M Feldman; Martha K Cathcart
Journal:  J Biol Chem       Date:  2011-08-30       Impact factor: 5.157

Review 4.  Signaling components of redox active endosomes: the redoxosomes.

Authors:  Fredrick D Oakley; Duane Abbott; Qiang Li; John F Engelhardt
Journal:  Antioxid Redox Signal       Date:  2009-06       Impact factor: 8.401

5.  Nitric oxide-mediated dilation of arterioles to intraluminal administration of aldosterone.

Authors:  Erwan Heylen; An Huang; Dong Sun; Gabor Kaley
Journal:  J Cardiovasc Pharmacol       Date:  2009-12       Impact factor: 3.105

Review 6.  Genomic and rapid effects of aldosterone: what we know and do not know thus far.

Authors:  Milla Marques Hermidorff; Leonardo Vinícius Monteiro de Assis; Mauro César Isoldi
Journal:  Heart Fail Rev       Date:  2017-01       Impact factor: 4.214

7.  Aldosterone activates NF-kappaB in the collecting duct.

Authors:  Valérie Leroy; Sophie De Seigneux; Victor Agassiz; Udo Hasler; Marie-Edith Rafestin-Oblin; Manlio Vinciguerra; Pierre-Yves Martin; Eric Féraille
Journal:  J Am Soc Nephrol       Date:  2008-11-05       Impact factor: 10.121

8.  Novel inflammatory markers in overweight women with and without polycystic ovary syndrome and following pharmacological intervention.

Authors:  L J Moran; C Meyer; S K Hutchison; S Zoungas; H J Teede
Journal:  J Endocrinol Invest       Date:  2009-10-15       Impact factor: 4.256

9.  Spironolactone prevents dietary-induced metabolic syndrome by inhibiting PI3-K/Akt and p38MAPK signaling pathways.

Authors:  H D Long; Y E Lin; M J Liu; L Y Liang; Z H Zeng
Journal:  J Endocrinol Invest       Date:  2013-04-23       Impact factor: 4.256

Review 10.  Skeletal muscle insulin resistance in endocrine disease.

Authors:  Melpomeni Peppa; Chrysi Koliaki; Panagiotis Nikolopoulos; Sotirios A Raptis
Journal:  J Biomed Biotechnol       Date:  2010-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.